Physician profile
Frank S Eldridge
NPI 1467814228
$8,236.88
in general payments reported to CMS, 2019-2025
40 companies · $1,487 in 2025
The $1,487 reported for 2025 was more than what 92% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $857 · 2022: $2,153 · 2023: $1,427 · 2024: $2,312 · 2025: $1,487.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,227.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,226.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $2,883.99 | 2021-2025 | Wavewriter Alpha Prime 16, Na, General - Pain Management |
| Novo Nordisk INC | $913.61 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $521.40 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $411.21 | 2021-2025 | Repatha, Otezla, Evenity |
| Astrazeneca Pharmaceuticals LP | $331.16 | 2021-2025 | Airsupra, Farxiga, Evusheld |
| Pfizer INC. | $318.26 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $306.74 | 2022-2025 | |
| Abbvie INC. | $261.56 | 2021-2024 | |
| Paratek Pharmaceuticals, INC. | $245.38 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $205.79 | 2021-2025 | Xifaxan, Trulance |
| Otsuka America Pharmaceutical, INC. | $205.06 | 2023-2025 | Rexulti |
| Novartis Pharmaceuticals Corporation | $178.96 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $130.37 | 2021-2025 | Jardiance, Synjardy, Tradjenta |
| Dexcom, INC. | $130.37 | 2024-2025 | Dexcom G6 Transmitter |
| Merck Sharp & Dohme LLC | $111.25 | 2021-2024 | Capvaxive, Verquvo, Belsomra |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $100.00 | 2022 | |
| Abbott Laboratories | $83.00 | 2023-2024 | Freestyle Libre 3 |
| E.R. Squibb & Sons, L.L.C. | $81.38 | 2022-2024 | Eliquis |
| Astellas Pharma US INC | $78.62 | 2021-2025 | Veozah |
| Corium, LLC | $73.04 | 2023 | Azstarys |
| Exact Sciences Corporation | $72.42 | 2023-2024 | Cologuard Collection Kit |
| Antares Pharma, INC. | $64.01 | 2021-2025 | Xyosted |
| Takeda Pharmaceuticals U.S.A., INC. | $63.72 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $61.76 | 2021-2023 | Xarelto |
| Corcept Therapeutics | $58.17 | 2023-2024 | Korlym |
| Glaxosmithkline, LLC. | $51.16 | 2025 | Trelegy Ellipta, Arexvy |
| Sanofi Pasteur INC. | $49.00 | 2022-2025 | |
| Sanofi-Aventis U.S. LLC | $36.92 | 2022 | |
| Supernus Pharmaceuticals, INC. | $24.75 | 2023 | Qelbree |
| Baxter Healthcare | $24.28 | 2024 | Hillrom - Ecg Electrode |
| Ibsa Pharma INC. | $20.63 | 2025 | Licart, Tirosint, Flector |
| Almatica Pharma LLC | $19.10 | 2021 | |
| Averitas Pharma INC. | $17.64 | 2023 | Qutenza |
| Amarin Pharma, INC. | $17.43 | 2022 | |
| Lundbeck LLC | $16.23 | 2024 | Rexulti |
| Phathom Pharmaceuticals, INC. | $15.26 | 2024 | Voquezna |
| Neurelis, INC. | $14.96 | 2021 | |
| Genentech USA, INC. | $13.71 | 2021 | |
| Idorsia Pharmaceuticals US INC | $13.13 | 2024 | Quviviq |
| Xeris Pharmaceuticals, INC. | $11.45 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Frank Eldridge listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.